• Mubritinib (TAK 165): Precision OXPHOS Inhibition in AML Res

  2026-07-20

  This thought-leadership article illuminates the mechanistic and strategic value of Mubritinib (TAK 165) as a mitochondrial electron transport chain complex I inhibitor in acute myeloid leukemia (AML) research. Drawing on recent landmark studies, we discuss how Mubritinib redefines metabolic targeting in cancer biology, bridging advanced mechanistic insights with practical protocol guidance for translational researchers. The piece contrasts Mubritinib's selectivity and workflow advantages—backed by APExBIO’s robust formulation—with the prevailing challenges in the field, and articulates a vision for integrating OXPHOS inhibition into next-generation cancer research pipelines.

• MHY1485: mTOR Activator for Autophagy and Follicle Studies

  2026-07-19

  MHY1485 is a benchmark mTOR activator that uniquely suppresses autophagic flux by inhibiting autophagosome-lysosome fusion, empowering researchers to dissect mTOR signaling in cell survival, metabolism, and ovarian development. Its dual action and robust solubility profile make it indispensable for reliable autophagy assays and advanced reproductive biology protocols.

• Small-Molecule uPAR Inhibition Blocks Breast Cancer Invasion

  2026-07-18

  The reference study pioneers small-molecule disruption of the uPAR–uPA interaction, identifying IPR-803 as a potent urokinase receptor inhibitor that impedes tumor cell invasion. This technical advance offers a validated pathway for developing targeted inhibitors of metastasis and supports translational research in aggressive cancers.

• Efficient Synthesis of Deuterium-Labeled Degarelix Acetate

  2026-07-17

  This study introduces a robust 13-step protocol for the synthesis of deuterium-labeled degarelix acetate, a third-generation GnRH receptor antagonist used as an internal standard in clinical metabolism studies. The approach leverages D2O/D3PO4 as a deuterium source, achieving high isotopic purity and supporting advanced pharmacokinetic research.

• 5-Methyl-CTP: Enhancing mRNA Stability in Advanced Synthesis

  2026-07-17

  5-Methyl-CTP is transforming mRNA synthesis by mimicking natural methylation, significantly improving transcript stability and translation efficiency. This guide details experimental workflows, troubleshooting strategies, and real-world mRNA vaccine applications that set APExBIO’s 5-Methyl-CTP apart for research and therapeutic development.

• Nitrocefin in β-Lactamase Assays: Precision, Pitfalls, and N

  2026-07-16

  Explore Nitrocefin as a chromogenic cephalosporin substrate for sensitive β-lactamase enzymatic activity measurement. This article delivers advanced assay strategies, practical protocol guidance, and a unique perspective on interpreting resistance mechanisms in emerging pathogens.

• LY-411575: Gamma-Secretase Inhibitor for Targeted Pathway Re

  2026-07-16

  LY-411575 stands out as an ultra-potent and selective gamma-secretase inhibitor, empowering researchers to dissect amyloid beta and Notch pathway biology with unprecedented precision. This guide details robust experimental workflows, troubleshooting strategies, and practical insights connecting recent advances in Alzheimer’s and cancer research.

• Resazurin Cell Viability Assay Kit: Precision in Apoptosis R

  2026-07-15

  The Resazurin Cell Viability Assay Kit streamlines sensitive, non-toxic quantification of cell health, offering unmatched flexibility for high-throughput and apoptosis studies. Its dual-mode detection and robust workflow outperform traditional assays, making it indispensable for modern cell viability analysis.

• Structure-Based Discovery of NSP15 Inhibitors in SARS-CoV-2

  2026-07-15

  This study uses structure-based virtual screening to identify thymopentin and oleuropein as potent inhibitors of the SARS-CoV-2 non-structural protein NSP15, an endoribonuclease critical for immune evasion. These findings highlight NSP15 as a promising antiviral drug target and provide a computational workflow for future inhibitor development.

• FAT4 Loss Drives Ferroptosis Resistance via PI3K/AKT in HCC

  2026-07-14

  This study reveals that loss of the tumor suppressor FAT4 in hepatocellular carcinoma promotes tumor growth and resistance to ferroptosis by activating the PI3K/AKT pathway. Pharmacological PI3K/AKT inhibition restores ferroptosis sensitivity, highlighting FAT4 as a potential biomarker and therapeutic target for overcoming drug resistance in HCC.

• Cycloastragenol Mitigates Bone Loss in Glucocorticoid-Induce

  2026-07-14

  This study demonstrates that cycloastragenol (CAG) prevents bone loss in a rat model of glucocorticoid-induced osteonecrosis of the femoral head (GIONFH) by directly inhibiting osteoclast activity. The findings clarify the pathogenic role of osteoclasts in GIONFH and highlight translational potential for osteoclast-targeted interventions in steroid-associated bone disorders.

• BMS-345541 Hydrochloride: Precision IKK Inhibition in Cell D

  2026-07-13

  BMS-345541 hydrochloride empowers researchers with highly selective IKK inhibition, enabling precise dissection of NF-κB-dependent pathways in inflammation and apoptosis. This article outlines actionable workflows, troubleshooting strategies, and unique translational applications—especially in T-ALL and RIPK1-regulated cell death—that differentiate this tool for advanced cancer and inflammation research.

• Tolazoline: Quantitative Affinity and Assay Optimization in

  2026-07-13

  Explore Tolazoline as a precise α2-adrenergic receptor antagonist, with a focus on quantitative binding, assay optimization, and translational utility in airway and islet research. This article uniquely bridges advanced receptor affinity measurement with practical protocol guidance.

• Azathramycin A: Expanding Macrolide Antibiotic Horizons in T

  2026-07-12

  Explore how Azathramycin A, a potent macrolide antibiotic, is redefining the study of Mycobacterium tuberculosis by enabling advanced research into protein synthesis inhibition and antibiotic resistance. This article delivers new insights and practical guidance for leveraging Azathramycin A in complex tuberculosis models.

• Methoxy-X04: Fluorescent Amyloid Beta Probe for Precise AD I

  2026-07-10

  Methoxy-X04 stands out as a brain-permeable, high-affinity fluorescent amyloid beta probe, empowering researchers to visualize both soluble and insoluble Aβ aggregates in vivo and ex vivo. Leveraging this tool, scientists can bridge mechanistic discoveries with translational breakthroughs in Alzheimer's disease research, optimizing imaging workflows and troubleshooting complex amyloid detection challenges.

454 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page